Literature DB >> 3975734

Retrograde endoscopy of the bypassed stomach segment after gastric bypass surgery: unexpected lesions.

D R Sinar, E G Flickinger, H K Park, R R Sloss.   

Abstract

Surgical measures for the treatment of morbid obesity include gastric bypass of the stomach and duodenum. We endoscopically evaluated the bypassed segments in 51 patients three to 24 months after a standard gastric bypass procedure. Retrograde endoscopy was successful in 33 of the patients (65%). There was significantly more gastritis by endoscopic grading in the distal bypassed segment than in the proximal part of the stomach. The gastritis in the bypassed segment was associated with pooled bile in 97% of the patients. The severity of gastritis did not appear to be related to the time after surgery and was as severe three months after surgery as it was at 24 months. Histologically, the gastritis was nonconfluent, and often the histologic and endoscopic findings were at variance. There was intestinal metaplasia in biopsy specimens from the distal pouch in four of the 33 patients. The mechanism for the high incidence of gastritis is unknown, but may be related to decreased antral motility due to distention of the proximal pouch with food. These patients require close observation for changes in the bypassed segment of stomach that may occur as a consequence of chronic inflammation.

Entities:  

Mesh:

Year:  1985        PMID: 3975734     DOI: 10.1097/00007611-198503000-00006

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  23 in total

1.  Duodenogastric bile reflux after gastric bypass: a cholescintigraphic study.

Authors:  Magnus Sundbom; Hans Hedenström; Sven Gustavsson
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

2.  MALT Lymphoma of the Gastric Remnant After Roux-en-Y Gastric Bypass.

Authors:  Ahmed Jawad; Allan H Bar; Demetri Merianos; Jing Zhou
Journal:  J Gastrointest Cancer       Date:  2012-09

3.  Investigation of the excluded stomach after Roux-en-Y gastric bypass: the role of percutaneous endoscopy.

Authors:  Kanwar-Rs Gill; J-Mark McKinney; Mark-E Stark; Ernest-P Bouras
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

4.  Obstruction of the bypassed stomach treated with percutaneous drainage: an alternative treatment for selected cases.

Authors:  E M López-Tomassetti Fernández; I Arteaga González; H Diaz-Luis; A Carrillo Pallares
Journal:  Obes Surg       Date:  2008-01-10       Impact factor: 4.129

5.  Evaluation of the excluded stomach by double-balloon endoscopy after laparoscopic Roux-en-Y gastric bypass.

Authors:  Nobumi Tagaya; Kazunori Kasama; Susumu Inamine; Osamu Zaha; Kazunari Kanke; Youichirou Fujii; Eiji Kanehira; Hideyuki Hiraishi; Keiichi Kubota
Journal:  Obes Surg       Date:  2007-09       Impact factor: 4.129

Review 6.  Controversy surrounding 'mini' gastric bypass.

Authors:  Kamal K Mahawar; William R J Carr; Shlok Balupuri; Peter K Small
Journal:  Obes Surg       Date:  2014-02       Impact factor: 4.129

7.  Endoscopic retrograde cholangiopancreatography and gastroduodenoscopy after Roux-en-Y gastric bypass.

Authors:  J Martinez; L Guerrero; P Byers; P Lopez; T Scagnelli; R Azuaje; B Dunkin
Journal:  Surg Endosc       Date:  2006-08-01       Impact factor: 4.584

8.  Absence of luminal intrinsic factor after gastric bypass surgery for morbid obesity.

Authors:  S P Marcuard; D R Sinar; M S Swanson; J F Silverman; J S Levine
Journal:  Dig Dis Sci       Date:  1989-08       Impact factor: 3.199

9.  Laparoscopic gastric bypass with subtotal gastrectomy for a super-obese patient with Biermer anemia.

Authors:  Maxime Sodji; Frédéric A Sebag; Jean Marc Catheline
Journal:  Obes Surg       Date:  2007-08       Impact factor: 4.129

10.  Bleeding duodenal ulcer after Roux-en-Y gastric bypass surgery: the value of laparoscopic gastroduodenoscopy.

Authors:  Hussain Issa; Osama Al-Saif; Sami Al-Momen; Bahaa Bseiso; Ahmed Al-Salem
Journal:  Ann Saudi Med       Date:  2010 Jan-Feb       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.